Etoposide par voie orale à faible dose pour le traitement du sarcome de Kaposi lié au SIDA en rechute ou en progression

Inclusion Criteria Concurrent Medication: Allowed: Maintenance therapy for opportunistic infections. Patients must have: HIV infection. Kaposi's sarcoma that has relapsed or progressed. Mucocutaneous lesions (15 or more) and/or symptomatic mucosal lesions and/or visceral Kaposi's sarcoma (symptomatic lymphedema qualifies patients in the absence of these three conditions). NO active acute opportunistic infections requiring treatment with myelosuppressive antibiotics (maintenance for OIs is permitted). Consent of parent or guardian if less than 18 years of age. NOTE: This study is approved for prisoner participation. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Other active malignancies except basal cell carcinoma of the skin, or carcinoma in situ of the cervix. Grade 3 or worse peripheral neuropathy. Altered mental status that would prevent informed consent or prevent study compliance. Patients with the following prior condition are excluded: Neuropsychiatric history. Prior Medication: Excluded: Prior etoposide. Any other anti-KS drugs within 14 days prior to study entry. Any investigational drug other than antiretrovirals within 14 days prior to study entry. Any prior investigational agent, if given as the ONLY prior treatment for KS. Prior Treatment: Excluded: Radiation therapy within 7 days prior to study entry. Continued alcohol consumption or continued intravenous drug use that would impair ability to comply with study requirements.